Annual Direct Medical Costs of Diabetic Foot Disease in Brazil: A Cost of Illness Study

Abstract

The aim of this study was to estimate the annual costs for the treatment of diabetic foot disease (DFD) in Brazil. We conducted a cost-of-illness study of DFD in 2014, while considering the Brazilian Public Healthcare System (SUS) perspective. Direct medical costs of outpatient management and inpatient care were considered. For outpatient costs, a panel of experts was convened from which utilization of healthcare services for the management of DFD was obtained. When considering the range of syndromes included in the DFD spectrum, we developed four well-defined hypothetical DFD cases: (1) peripheral neuropathy without ulcer, (2) non-infected foot ulcer, (3) infected foot ulcer, and (4) clinical management of amputated patients. Quantities of each healthcare service was then multiplied by their respective unit costs obtained from national price listings. We then developed a decision analytic tree to estimate nationwide costs of DFD in Brazil, while taking into the account the estimated cost per case and considering epidemiologic parameters obtained from a national survey, secondary data, and the literature. For inpatient care, ICD10 codes related to DFD were identified and costs of hospitalizations due to osteomyelitis, amputations, and other selected DFD related conditions were obtained from a nationwide hospitalization database. Direct medical costs of DFD in Brazil was estimated considering the 2014 purchasing power parity (PPP) (1 Int$ = 1.748 BRL). We estimated that the annual direct medical costs of DFD in 2014 was Int$ 361 million, which denotes 0.31% of public health expenses for this period. Of the total, Int$ 27.7 million (13%) was for inpatient, and Int$ 333.5 million (87%) for outpatient care. Despite using different methodologies to estimate outpatient and inpatient costs related to DFD, this is the first study to assess the overall economic burden of DFD in Brazil, while considering all of its syndromes and both outpatients and inpatients. Although we have various reasons to believe that the hospital costs are underestimated, the estimated DFD burden is significant. As such, public health preventive strategies to reduce DFD related morbidity and mortality and costs are of utmost importance.

The Cost of Chronic Wounds in Argentina: An Estimation of the Burden in a Public Hospital

“…The management of chronic wounds is complex, time-consuming, and requires high level of resources [3], and can result in an important economic and public health burden, especially in low and middle income countries [13]. In Argentina healthcare is provided by both public and private sectors.…”

“…Limited evidence is available on the costs of CLLU in Latin American countries. One study in Brazil with DFU showed an estimated average cost for outpatient management that range fromUS$400 to US$1,600 [13] and the average hospitalization cost per patient range from US$400 to US$2,700 [13]. Meanwhile, in Peru the annual cost per patient hospitalization range from US$1,022 to US$7,360 according to the treatment applied [14].…”

Adenosine diphosphate contributes to wound healing in diabetic mice through P2Y1and P2Y12receptors activation

“…Chronic wounds are reported to affect around 6.5 million patients just in USA; the estimated annually cost is more than US$ 25 billion for wound-related complications and healthcare system. In Brazil, the most populous country in Latin America, about 40 to 60% of non-traumatic lower limb amputations occur in diabetic patients; whereas, about 85% are related to foot ulcers [5][6][7].…”

Cost of treatment and reduction achieved by chronic ulcer in diabetic patients - a comparison between hydrogel and human recombinant Epidermal Growth Factor

“…Currently, in addition to the comorbidities associated with diabetes, the increasing life expectancy of these patients also increases the incidence of these conditions [4]. In developing countries such as Brazil, evidence suggests that lifetime occurrence of diabetic ulcers is between 19% and 34% [5].…”

“…The health costs of treating chronic ulcers in diabetic patients with venous leg ulcers and diabetic foot ulcers are five times higher than in diabetic individuals with no ulcer [4,7]. Those costs are mainly related to hospitalizations, more frequent in diabetics, but also to the care costs of treatment and follow-up of outpatient clinical management [8][9][10][11].…”